Thu, Jul 24, 2014, 12:32 PM EDT - U.S. Markets close in 3 hrs 28 mins


% | $
Click the to save as a favorite.

Pfizer Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • bigcoinman2002 bigcoinman2002 Nov 11, 2012 7:54 AM Flag

    Mannkind-MNKD Afrezza Approval Run-Up

    Unlike PFEs failed product, Afrezza is a better,fast acting bolus insulin that is in the blood in @15 minutes and leaves a few hours later. No hypoglycemic issues.
    Exubera was a me too drug with a Bong like dispenser and no clear medical advantage which is why it wouldn't get the insurance reimbursements. Afrezza, per the FDA request, is also being tested for type 2 which means it could be the super blockbuster drug for the next dozen or more years.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Other than convenience, no inhaled insulin product has an efficacy qdvantage over injuected insulin and that is why insurers won't reimburse for it. Fai9lure to reimburse has nothing whatsoever to do whether the device is bong-like or fashionable. NVO and LLY clearly saw the handwriting on the wall and scrapped their own promising inhaled insulin stage 3 products within weeks of Pfizer taking Exubera off the market in October 2007.

      Due to reimbursement problems here and abroad, there would be such a small effective market for Afrreeza even if approved that no big pharma would be even remotely interested in a partnmership. And MNKD simply doesn't have the ssales structure to go it on its own; they MUST have a partnership.

      Unless the insurers completely reverse themselves which they are most-unlikely to do, MNKD is a doomed company.

      Sentiment: Buy

30.43+0.04(+0.13%)12:32 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.